LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

17.23 -2.55

Visão Geral

Variação de preço das ações

24h

Atual

Mín

17.23

Máximo

17.53

Indicadores-chave

By Trading Economics

Rendimento

9.2M

-16M

Vendas

16M

82M

Margem de lucro

-19.491

Funcionários

342

EBITDA

6.7M

-12M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+25.27% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

347M

2.1B

Abertura anterior

19.78

Fecho anterior

17.23

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de set. de 2025, 22:41 UTC

Grandes Movimentos do Mercado

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 de set. de 2025, 16:04 UTC

Grandes Movimentos do Mercado

Upexi Shares Climb on Solana Gains

12 de set. de 2025, 15:03 UTC

Grandes Movimentos do Mercado

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

13 de set. de 2025, 08:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

12 de set. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

12 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de set. de 2025, 20:09 UTC

Ganhos

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 de set. de 2025, 19:23 UTC

Conversa de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 de set. de 2025, 19:16 UTC

Conversa de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 de set. de 2025, 19:03 UTC

Conversa de Mercado

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 de set. de 2025, 18:59 UTC

Conversa de Mercado

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 de set. de 2025, 18:38 UTC

Conversa de Mercado
Ganhos

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 de set. de 2025, 18:33 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 de set. de 2025, 18:22 UTC

Conversa de Mercado

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 de set. de 2025, 16:56 UTC

Conversa de Mercado

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 de set. de 2025, 16:22 UTC

Ganhos

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 de set. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de set. de 2025, 16:19 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 de set. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

12 de set. de 2025, 16:11 UTC

Ganhos

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 de set. de 2025, 15:37 UTC

Conversa de Mercado

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 de set. de 2025, 15:22 UTC

Conversa de Mercado

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 de set. de 2025, 15:07 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 de set. de 2025, 14:34 UTC

Conversa de Mercado

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 de set. de 2025, 14:10 UTC

Conversa de Mercado

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 de set. de 2025, 13:58 UTC

Conversa de Mercado

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 de set. de 2025, 13:58 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 de set. de 2025, 13:57 UTC

Ganhos

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 de set. de 2025, 13:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 de set. de 2025, 13:56 UTC

Conversa de Mercado

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

25.27% parte superior

Previsão para 12 meses

Média 22.16 USD  25.27%

Máximo 29 USD

Mínimo 14.29 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

7

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

12.42 / 14.93Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat